摘要
目的探讨结直肠癌肝转移患者血清中CD44和CD54含量与结直肠癌肝转移发生发展的关系,寻找一个稳定的早期诊断结直肠癌肝转移的生物学指标。方法应用酶联免疫吸附测定方法(ELISA)检测38例结直肠癌和21例结直肠癌肝转移患者以及40例健康成人(正常对照组)的血清CD44和CD54含量,并比较血清中CD44和CD54含量在治疗前后的变化。结果结直肠癌肝转移组和结直肠癌组血清中CD44和CD54含量明显高于正常对照组,且结直肠癌肝转移组较结直肠癌组含量也明显增高。结直肠癌肝转移组和结直肠癌组治疗后的血清CD44和CD54含量比治疗前下降。结论CD44和CD54可以作为临床早期诊断结直肠癌肝转移的生物学指标,同时也可以作为监测结直肠癌和结直肠癌肝转移预后的客观指标。
Objective To explore the relationship between the serum levels of CD44 and CD54 and the development of liver metastasis in colorectal cancer, and to find a stable biological marker for the early diagnosis of liver metastasis in colorectal cancer. Methods ELISA was used to measure the serum levels of CD44 and CD54 in 38 colorectal cancer patients,21 colorectal cancer patients with liver metastasis and 40 healthy volunteers (as control). The serum levels of CD44 and CD54 before and after treatment were compared. Results The serum levels of CD44 and CD54 in the colorectal cancer group and liver metastasis group were significantly higher than those in the control group. The levels were higher in liver metastasis group than that in colorectal cancer group and decreased both in two groups after operation. Conclusions CD44 and CD54 can be used as biological markers for early clinical diagnosis of liver metastasis and prognostic factor in colorectal cancer.
出处
《中华胃肠外科杂志》
CAS
2004年第2期140-143,共4页
Chinese Journal of Gastrointestinal Surgery
